文献速递肾小球疾病遗传性与小管间质肾病

Alport综合征的新治疗选择

New therapeutic options for Alport syndrome.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本文综述了Alport综合征(AS)三种遗传方式的特点,并重点讨论了针对该病的新药或治疗靶点。多数治疗研究并非针对IV型胶原异常本身,而是聚焦于相关的炎症和纤维化。AS可能作为多种慢性肾脏病潜在药物的概念验证模型。

要点

  • AS有三种遗传方式:常染色体显性、常染色体隐性和X连锁。
  • 治疗研究多靶向炎症和纤维化而非IV型胶原组成异常。
  • AS患者年轻且合并症少,有利于临床试验开展。

核心结论

  • AS治疗研究主要针对相关炎症和纤维化,而非主要异常IV型胶原组成。
  • AS可作为多种慢性肾脏病潜在药物的概念验证。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • AS是最常见的遗传性肾病之一,仅次于常染色体显性多囊肾病。
  • AS有三种遗传方式:常染色体显性、常染色体隐性和X连锁,部分解释了疾病谱广泛。
  • AS患者年轻且合并症少,有利于临床试验。

临床怎么用

  • AS治疗研究应关注炎症和纤维化通路。
  • AS患者年轻合并症少的特点可促进临床试验开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alport syndrome (AS) is the most frequent inherited kidney disease after autosomal dominant polycystic kidney disease. It has three different patterns of inheritance-autosomal dominant, autosomal recessive and X-linked-which in part explains the wide spectrum of disease, ranging from isolated microhaematuria to end-stage renal disease early in life. The search for a treatment for AS is being pursued vigorously, not only because of the obvious unmet need but also because AS is a rare disease and any drug approved will have an orphan drug designation with its various benefits. Moreover, AS patients are quite young with very few comorbidities, which facilitates clinical trials. This review identifies the particularities of each pattern of inheritance but focuses mainly on new drugs or therapeutic targets for the disease. Most treatment-related investigations are directed not at the main abnormality in AS, namely collagen IV composition, but rather at the associated inflammation and fibrosis. Thus, AS may serve as a proof of concept for numerous drugs of potential value in many diseases that cause chronic kidney disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Torra R, Furlano M. New therapeutic options for Alport syndrome. Nephrol Dial Transplant. 2019. PMID: 31190059. doi:10.1093/ndt/gfz131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。